AVASTIN (bevacizumab), monoclonal antibody

ONCOLOGY - Focus

Opinions on drugs - Posted on Oct 12 2016

Re-assessment of the actual benefit and the improvement in actual benefit

In colorectal cancer, AVASTIN has Marketing Authorisation, in combination with fluoropyrimidine-based chemotherapy, as second-line treatment of metastatic colorectal cancer in adults.
In a new study, a low gain in overall survival (1.4 months) was observed, and in another study, a lack of gain was observed, with an increase in adverse events in both studies.
No comparison to an anti-EGFR drug in case of wild-type RAS tumour is available.

Substantial

no clinical added value

Évaluation des médicaments

All our publications

My account